Jonathan Hatton, DO
Family Medicine · Whitesburg, KYNPI 1629362397
Payments from drug & device makers
Across 163 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$579
- Indivior Inc.$546
- Lilly USA, LLC$210
- GSK$172
- Novo Nordisk$150
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$104
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,87399%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $579 |
| Indivior Inc. | 23 | $546 |
| Lilly USA, LLC | 14 | $210 |
| GSK | 10 | $172 |
| Novo Nordisk | 9 | $150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $104 |
| Braeburn Inc. | 4 | $94 |
| Pfizer | 6 | $92 |
| Johnson & Johnson | 1 | $91 |
| Bayer | 5 | $85 |
| Boehringer Ingelheim | 5 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Amgen | 3 | $63 |
| AstraZeneca | 2 | $61 |
| Novartis | 4 | $57 |
| Supernus Pharmaceuticals, Inc. | 4 | $56 |
| Vertex | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Kvk-tech, Inc. | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Merck | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Pear Therapeutics (US), Inc. | 1 | $12 |
How this compares
$2,906 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $97,294 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 673 | $82,185 |
| FarxigaDapagliflozin Propanediol | 111 | $80,430 |
| MounjaroTirzepatide | 74 | $79,812 |
| SublocadeBuprenorphine | 39 | $76,649 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $68,788 |
| JardianceEmpagliflozin | 63 | $51,892 |
| EliquisApixaban | 65 | $49,116 |
| LinzessLinaclotide | 66 | $47,291 |
| KerendiaFinerenone | 34 | $28,000 |
| JanuviaSitagliptin Phosphate | 28 | $25,479 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 60 | $24,485 |
| Nurtec OdtRimegepant Sulfate | 25 | $24,229 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $20,364 |
| BelbucaBuprenorphine Hcl | 24 | $19,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $61 | $109,713179 claims |
| Indivior Inc.Sublocade, Suboxone | $546 | $101,13499 claims |
| Novo NordiskOzempic | $150 | $97,29497 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $21 | $82,185673 claims |
| Lilly USA, LLCMounjaro | $210 | $79,81274 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat | $79 | $77,078105 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $92 | $76,850103 claims |
| GSKTrelegy Ellipta, Shingrix | $172 | $70,871112 claims |
| AbbVieLinzess, Creon | $579 | $64,01078 claims |
| BayerKerendia | $85 | $28,00034 claims |
| MerckJanuvia | $14 | $25,47928 claims |
| Johnson & JohnsonXarelto | $91 | $10,87916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Whitesburg
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.